Edgewise Therapeutics, Inc. EWTX Finance Lease Right Of Use Asset Amortization
Finance Lease Right Of Use Asset Amortization at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAssetAmortization.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s finance lease right of use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s finance lease right of use asset amortization?
- Edgewise Therapeutics, Inc. (EWTX) reported finance lease right of use asset amortization of $53K in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s finance lease right of use asset amortization changed year-over-year?
- Edgewise Therapeutics, Inc.'s finance lease right of use asset amortization increased by 29.3% year-over-year, from $41K to $53K.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s finance lease right of use asset amortization?
- Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s finance lease right of use asset amortization has grown at a 2.3% compound annual growth rate (CAGR), from $170K to $182K.
- What does finance lease right of use asset amortization mean?
- This represents the non-cash expense associated with the amortization of right-of-use assets recognized under finance lease arrangements. It reflects the systematic consumption of the economic benefits of leased assets over the lease term. Monitoring this helps analysts distinguish between cash-based lease payments and the accounting-driven depreciation of capitalized lease obligations.